Dunedin probiotics manufacturer Blis Technologies has predicted it will move from 12 years of losses - amounting to more than $32million - to booking its first profit, next financial year.
Blis chief executive Brian Watson said in a market update yesterday Blis had increased its trading revenues for the full year to March by 123% to $5.6million, and will report a small deficit in earnings before interest, tax depreciation and amortisation.
Its full-year annual audited financial results are scheduled for release on May 23.
Mr Watson yesterday said Blis expects to achieve trading revenues of more than $8million for the 2017 financial year, and record a net profit after tax.
In late-January, Blis overcame a major hurdle to getting its probiotic products into the United States market, with the powerful Food and Drug Administration issuing what is commonly known as "generally recognised as safe'' (Gras) approval.
Blis was founded on a natural antibiotic to control streptococcal throat infections and went on the develop lozenges, sprays and additives for dairy products, its mainstay brand being its Blis K12 throat guard.
